$8.98
1.01% today
Nasdaq, Feb 28, 04:51 pm CET
ISIN
US45257U1088
Symbol
IMNM
Sector
Industry

Immunome Inc Stock price

$8.89
-0.80 8.26% 1M
-6.08 40.61% 6M
-1.73 16.29% YTD
-17.11 65.81% 1Y
+2.31 35.11% 3Y
-4.56 33.90% 5Y
-4.56 33.90% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.69 7.20%
ISIN
US45257U1088
Symbol
IMNM
Sector
Industry

Key metrics

Market capitalization $752.76m
Enterprise Value $515.35m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 50.87
P/S ratio (TTM) P/S ratio 74.31
P/B ratio (TTM) P/B ratio 2.50
Revenue growth (TTM) Revenue growth -0.62%
Revenue (TTM) Revenue $10.13m
EBIT (operating result TTM) EBIT $-310.78m
Free Cash Flow (TTM) Free Cash Flow $-92.59m
Cash position $240.13m
EPS (TTM) EPS $-8.12
P/E forward negative
P/S forward 80.03
EV/Sales forward 54.79
Short interest 11.14%
Show more

Is Immunome Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Immunome Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Immunome Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Immunome Inc forecast:

Buy
100%

Financial data from Immunome Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
1% 1%
100%
- Direct Costs 1.76 1.76
141% 141%
17%
8.37 8.37
12% 12%
83%
- Selling and Administrative Expenses 29 29
102% 102%
284%
- Research and Development Expense 289 289
1,586% 1,586%
2,849%
-309 -309
1,309% 1,309%
-3,050%
- Depreciation and Amortization 1.76 1.76
141% 141%
17%
EBIT (Operating Income) EBIT -311 -311
1,271% 1,271%
-3,068%
Net Profit -305 -305
1,290% 1,290%
-3,014%

In millions USD.

Don't miss a Thing! We will send you all news about Immunome Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunome Inc Stock News

Neutral
Business Wire
3 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences in March 2025: TD Cowen 45th Annual Health Care Conference Conference Dates: March 3-5, 2025 Presentation Date/Time: March 4, 2025, 1:10 p.m. ET Lee...
Neutral
Business Wire
22 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purc...
Neutral
Business Wire
28 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 share...
More Immunome Inc News

Company Profile

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Head office United States
CEO Clay Siegall
Employees 55
Founded 2006
Website www.immunome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today